H. R. CASDORPH, M.D., PH.D.
To the editor: I have read with interest the article, "Hypoprothrombinemia and Hemorrhage Associated with Cholestyramine Therapy," by Gross and Brotman (Ann Intern Med 72:95-96, 1970). It is perhaps noteworthy that this is the first reported hemorrhagic complication from this drug, which has been used for over 10 years.
A historical overview seems indicated. Cholestyramine was initially developed to relieve the pruritus associated with partial biliary obstruction usually in patients with primary biliary cirrhosis. The concern with prothrombin production was logical since prothrombin is produced in the liver, and most of the first patients to be treated with this drug
CASDORPH HR. Safe Uses of Cholestyramine. Ann Intern Med. ;72:759–760. doi: 10.7326/0003-4819-72-5-759
Download citation file:
Published: Ann Intern Med. 1970;72(5):759-760.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use